Metabolic changes after H2 15O-positron emission tomography with acetazolamide in a patient with moyamoya disease: Case report and review of previous cases

Journal of Neurosurgical Anesthesiology

Volumn 15, Issue 2, 2003, Pages 131-139

  Muroi, Carl ^a   Yonekawa, Yasuhiro ^a   Khan, Nadia ^a   Pangalu, Athina ^a   Keller, Emanuela ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Acetazolamide; Cerebral blood flow; H2 15O PET; Moyamoya disease; Perioperative treatment

Indexed keywords

ACETAZOLAMIDE; DEUTERIUM; OXYGEN 15;

ACIDOSIS; ADULT; ARTICLE; BRAIN BLOOD FLOW; BRAIN EDEMA; BRAIN INFARCTION; BRAIN ISCHEMIA; BYPASS SURGERY; CASE REPORT; EVALUATION; FEMALE; HUMAN; HYPERCAPNIA; HYPOCAPNIA; HYPOTENSION; HYPOVOLEMIA; MOYAMOYA DISEASE; PERIOPERATIVE PERIOD; PH MEASUREMENT; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK FACTOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURGICAL TECHNIQUE;

ACETAZOLAMIDE; ACIDOSIS; ADULT; BLOOD PRESSURE; CAROTID ARTERIES; CEREBRAL ANGIOGRAPHY; CEREBRAL REVASCULARIZATION; FATAL OUTCOME; FEMALE; HUMANS; INTRAOPERATIVE COMPLICATIONS; MOYAMOYA DISEASE; OXYGEN RADIOISOTOPES; PARESIS; POSTOPERATIVE COMPLICATIONS; RADIOPHARMACEUTICALS; SEIZURES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0037382647     PISSN: 08984921     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008506-200304000-00011     Document Type: Article

References (29)

1. Yonekawa Y, Taub E. Moyamoya disease: status 1998. The Neurologist 1999;5:13-23.
2. Goto Y, Yonekawa Y. Worldwide distribution of moyamoya disease. Neurol Med Chir (Tokyo) 1992;32:883-6.
3. Yonekawa Y, Ogata N, Kaku Y, et al. Moyamoya disease in Europe, past and present status. Clin Neurol Neurosurg 1997;99(suppl 2):58-60.
4. Iwama T, Hashimoto N, Yonekawa Y. The relevance of hemodynamic factors to perioperative ischemic complications in childhood moyamoya disease. Neurosurgery 1996;38:1120-6.
5. Sumikawa K, Nagai H. Moyamoya disease and anesthesia. Anesthesiology 1983;58:204-5.
6. Sakamoto T, Kawaguchi M, Kurehara K, et al. Postoperative neurologic deterioration following the revascularization surgery in children with moyamoya disease. J Neurosurg Anesthesiol 1998;10:37-41.
7. Sakamoto T, Kawaguchi M, Kurehara K, et al. Risk factors for neurologic deterioration after revascularization surgery in patients with moyamoya disease. Anesth Analg 1997;85:1060-5.
8. Nomura S, Kashiwagi S, Uetsuka S, et al. Perioperative management protocols for children with moyamoya disease. Childs Nerv Syst 2001;17:270-4.
9. Kansha M, Irita K, Takahashi S, et al. Anesthetic management of children with moyamoya disease. Clin Neurol Neurosurg 1997;99 (suppl 2):110-3.
10. Komiyama M, Nishikawa M, Yasui T, et al. Reversible pontine ischemia caused by acetazolamide challenge. AJNR 1997;18:1782-4.
11. Lee YT, Wu JC, Chan FK. Acetazolamide-induced Gerstmann syndrome. Int J Clin Pract 1999;53:560-1.
12. Vorstrup S, Brun B, Lassen NA. Evaluation of the cerebral vasodilatatory capacity by the acetazolamide test before EC-IC bypass surgery in patients with occlusion of the internal carotid artery. Stroke 1986;17:1291-8.
13. Brechue WF, Stager JM, Lukaski HC. Body water and electrolyte responses to acetazolamide in humans. J Appl Physiol 1990;69:1397-401.
14. Epstein DL, Grant WM. Carbonic anhydrase inhibitor side effects. Arch Ophtalmol (Paris) 1977;95:1378-82.
15. Heller I, Halevy J, Cohen S, et al. Significant metabolic acidosis induced by acetazolamide. Not a rare complication. Arch Intern Med 1985;145:1815-7.
16. Rousseau P, Fuentevilla CA. Acetazolamide and salicylate interaction in the elderly: a case report. J Am Geriatr Soc 1993;41:868-9.
17. Maisey DN, Brown RD. Acetazolamide and symptomatic metabolic acidosis in mild renal failure. Br Med J (Clin Res Ed) 1981;283:1527-8.
18. Elinav E, Ackerman Z, Gottehrer NP, et al. Recurrent life-threatening acidosis induced by acetazolamide in a patient with diabetic type IV renal tubular acidosis. Ann Emerg Med 2002;40:259-60.
19. - formation in CNS. J Appl Physiol 1980;49:778-83.
20. Javaheri S, Kennely J, Runck CD, et al. Cerebrospinal fluid ions in metabolic acidosis in dogs: effects of acetazolamide. J Appl Physiol 1986;61:633-9.
21. 2 and on pial vessels. Stroke 1977;8:358-60.
22. Wahl M, Deetjen P, Thurau K, et al. Micropuncture evaluation of the importance of perivascular pH for the arteriolar diameter on the brain surface. Pfluegers Arch 1970;316:152-63.
23. Britton SL, Lorenz OL, Davies DG. Effect of cerebral extracellular fluid acidity on total and regional cerebral blood flow. J Appl Physiol 1979;47:818-26.
24. Regli F, Yamaguchi T, Waltz AG. Effects of acetazolamide on cerebral ischemia and infarction after experimental occlusion of middle cerebral artery. Stroke 1971;2:456-60.
25. Sato K, Shirane R, Masato K, et al. Effect of inhalational anesthesia on cerebral circulation in moyamoya disease. J Neurosurg Anesthesiol 1999;11:25-30.
26. Oshima H, Katayama Y, Hirayama T. Intracranial steal phenomenon associated with global hyperemia in moyamoya disease during revascularization surgery. J Neurosurg 2000;92:949-54.
27. Maren TH. Carbonic anhydrase: chemistry, physiology, and inhibition. Physiol Rev 1967;47:597-765.
28. Kuwabara Y, Ichiya Y, Sasaki M, et al. Cerebral hemodynamics and metabolism in moyamoya disease - a positron emission tomography study. Clin Neurol Neurosurg 1997;99(suppl 2):74-8.
29. Ikezaki K, Matsushima T, Kuwabara Y, et al. Cerebral circulation and oxygen metabolism in childhood moyamoya disease: a positron emission tomography study. J Neurosurg 1994;81:843-50.